Novozymes.info

The timeline behind novozymes.info

Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.

Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.

ARBITRATION AND MEDIATION CENTER ADMINISTRATIVE PANEL DECISION Novozymes A/S v. Andy Threeso Case No. D2026-1182 1. The Parties The Complainant is Novozymes A/S, Denmark, represented by Abion AB, Sweden. The Respondent is Andy Threeso, Indonesia. 2. The Domain Name and Registrar The disputed domain name <novozymes.info> (the “Domain Name”) is registered with Dynadot Inc (the “Registrar”). 3. Procedural History The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on March 19, 2026. On March 19, 2026, the Center transmitted by email to the Registrar a request for registrar verification in connection with the Domain Name. On March 21, 2026, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the Domain Name which differed from the named Respondent (Dynadot Privacy Service Super Privacy Service LTD c/o Dynadot) and contact information in the Complaint. The Center sent an email communication to the Complainant on March 24, 2026, providing the registrant and contact information disclosed by the Registrar, and inviting the Complainant to submit an amendment to the Complaint. The Complainant filed an amended Complaint on March 27, 2026. The Center verified that the Complaint together with the amended Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”). In accordance with the Rules, paragraphs 2 and 4, the Center formally notified the Respondent of the Complaint, and the proceedings commenced on March 31, 2026. In accordance with the Rules, paragraph 5, the due date for Response was April 20, 2026. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on April 21, 2026. page 2 The Center appointed Piotr Nowaczyk as the sole panelist in this matter on April 29, 2026. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7. 4. Factual Background The Complainant is a Danish biosolutions company established in 2000, operating in the field of industrial enzymes and microbial technologies. Its products and services are used in sectors including food and beverages, household care, agriculture, bioenergy, and pharmaceuticals. The Complainant is the owner of numerous NOVOZYMES trademark registrations, including: - the International Trademark Registration for NOVOZYMES (figurative trademark) No. 1272389, registered on July 17, 2015; - the International Trademark Registration for NOVOZYMES (word trademark) No. 733758, registered on April 18, 2000; and - the European Union Trade Mark Registration for NOVOZYMES (word trademark) No. 001522291, registered on March 10, 2003. The Complainant is also the owner of numerous domain names incorporating its NOVOZYMES trademark, including <novozymes.com>, <novozymes.net>, <novozymes.org>, and <novozymes.eu>. The Domain Name was registered on February 17, 2021. At the time of the filing of the Complaint, the Domain Name resolved to a website displaying content related to “Free Blizzard Battlenet & WoW Gift Cards Online Tool”, including purported generators for Blizzard and World of Warcraft gift cards and subscription codes (the “Website”). The Website also contained blog and privacy policy pages, as well as forms requesting user information. As of the date of this Decision, the Domain Name does not resolve to any active website. On February 17, 2026, February 27, 2026, and March 5, 2026, the Complainant sent cease-and-desist letters to the Respondent through the Registrar. The Complainant submits that no response was received. 5. Parties’ Contentions A. Complainant The Complainant contends that it has satisfied each of the elements required under the Policy for a transfer of the Domain Name. First, the Complainant contends that the Domain Name is identical to the trademark in which the Complainant has rights. Second, the Complainant argues that the Respondent has neither rights nor legitimate interests in the Domain Name. Third, the Complainant submits that the Domain Name was registered and is being used in bad faith. B. Respondent The Respondent did not reply to the Complainant’s contentions. page 3 6. Discussion and Findings Paragraph 4(a) of the Policy places a burden on the Complainant to prove the presence of three separate elements, which can be summarized as follows: (i) the Domain Name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights; (ii) the Respondent has no rights or legitimate interests in the Domain Name; and (iii) the Domain Name has been registered and is being used in bad faith. The applicable standard of proof in UDRP cases is the “balance of probabilities” or “preponderance of the evidence”; some panels have also expressed this as an “on balance” standard. Under this standard, a party should demonstrate to a panel’s satisfaction that it is more likely than not that a claimed fact is true. See section 4.2 of the WIPO Overview of WIPO Panel Views on Select UDRP Questions (“WIPO Overview 3.1”). A. Identical or Confusingly Similar Under the first element, the Complainant must establish that the Domain Name is identical or confusingly similar to the trademark in which the Complainant has rights. The Complainant holds valid registrations for the NOVOZYMES trademark. The Domain Name incorporates this trademark in its entirety. As numerous UDRP panels have held, in cases where a domain name incorporates the entirety of a trademark, the domain name will normally be considered confusingly similar to that mark. See section 1.7 of the WIPO Overview 3.1. The generic Top-Level Domain (“gTLD”) “.info” in the Domain Name is viewed as a standard registration requirement and as such is typically disregarded under the first element confusing similarity test. See section 1.11.1 of the WIPO Overview 3.1. Given the above, the Panel finds that the Domain Name is identical to the Complainant’s NOVOZYMES trademark. Thus, the Panel finds the first element of the Policy has been established. B. Rights or Legitimate Interests Under the second element, the Complainant must prove that the Respondent has no rights or legitimate interests in the Domain Name. A right or legitimate interest in the Domain Name may be established, in accordance with paragraph 4(c) of the Policy, if the Panel finds any of the following circumstances: (i) that the Respondent has used or made preparations to use the Domain Name or a name corresponding to the Domain Name in connection with a bona fide offering of goods or services prior to the dispute; or (ii) that the Respondent is commonly known by the Domain Name, even if the Respondent has not acquired any trademark rights; or (iii) that the Respondent is making a legitimate noncommercial or fair use of the Domain Name without intent for commercial gain to misleadingly divert consumers or to tarnish the trademark. page 4 In the present case, the Panel finds that the Complainant has established a prima facie case that the Respondent does not have any rights or legitimate interests in the Domain Name, and the burden of production of evidence shifts to the Respondent. See section 2.1 of the WIPO Overview 3.1. Although given the opportunity, the Respondent has not submitted any evidence indicating that any of the circumstances foreseen in paragraph 4(c) of the Policy are present in this case. On the contrary, it results from the evidence on record that the Complainant’s NOVOZYMES trademark registrations predate the Respondent’s registration of the Domain Name. There is no evidence in the case record that the Complainant has licensed or otherwise permitted the Respondent to use the NOVOZYMES trademark or to register the Domain Name incorporating this trademark. There is also no evidence to suggest that the Respondent has been commonly known by the Domain Name. Moreover, the composition of the Domain Name carries a risk of implied affiliation with the Complainant. See section 2.5.1 of the WIPO Overview 3.1. Furthermore, it results from the evidence on record that the Respondent does not make use of the Domain Name in connection with a bona fide offering of goods or services, nor does it make a legitimate noncommercial or fair use of the Domain Name. On the contrary, at the time of the filing of the Complaint, the Domain Name resolved to the Website promoting “Free Blizzard Battlenet & WoW Gift Cards Online Tool”, including purported gift card and subscription code generators, together with blog and privacy policy pages and forms requesting user information. Such use of the Domain Name in this case does not confer rights or legitimate interests on the Respondent. In sum, the Respondent has failed to invoke any circumstances, which could demonstrate, pursuant to paragraph 4(c) of the Policy, any rights or legitimate interests in respect of the Domain Name. Thus, there is no evidence in the case file that refutes the Complainant’s prima facie case. The Panel concludes that the second element of the Policy has been established. C. Registered and Used in Bad Faith Under the third element, the Complainant must prove that the Domain Name has been registered and is being used in bad faith. Bad faith under the UDRP is broadly understood to occur where a respondent takes unfair advantage of or otherwise abuses a complainant’s mark. See section 3.1 of the WIPO Overview 3.1. Under paragraph 4(b) of the Policy, evidence of bad faith registration and use includes, without limitation: (i) circumstances indicating the domain name was registered or acquired primarily for the purpose of selling, renting, or otherwise transferring the domain name registration to the owner of a trademark or to a competitor of the trademark owner, for valuable consideration in excess of the documented out-of-pocket costs directly related to the domain name; or (ii) circumstances indicating that the domain name was registered in order to prevent the owner of a trademark from reflecting the mark in a corresponding domain name, provided it is a pattern of such conduct; or (iii) circumstances indicating that the domain name was registered primarily for the purpose of disrupting the business of a competitor; or (iv) circumstances indicating that the domain name has intentionally been used in an attempt to attract, for commercial gain, Internet users to a website or other online location, by creating a likelihood of confusion with a trademark as to the source, sponsorship, affiliation, or endorsement of the website or location or of a product or service on a website or location. page 5 In the present case, as indicated above, the Complainant’s rights in the NOVOZYMES trademark predate the registration of the Domain Name. This Panel finds that the Respondent was or should have been aware of the Complainant’s NOVOZYMES trademark at the time of registration. This finding is supported by the composition of the Domain Name, which consists exclusively of the Complainant’s NOVOZYMES trademark. Moreover, it has been proven to the Panel’s satisfaction that the NOVOZYMES trademark is well known and highly distinctive, being associated with the Complainant, particularly in the fields of biotechnology, biosolutions, enzymes, and industrial innovation. Thus, the Respondent could not ignore the reputation of the NOVOZYMES trademark. Furthermore, at the time the Complaint was filed, the Domain Name resolved to the Website offering purported gift card and subscription code generators and requesting user information. As of the date of this Decision, the Domain Name does not resolve to any active website. The Panel finds, having regard to the totality of the circumstances of the case, that the Respondent has intentionally attempted to attract, for commercial gain, Internet users to the website by creating a likelihood of confusion with the Complainant’s trademark as to the source, sponsorship, affiliation, or endorsement of this website. Moreover, as evidenced by the Complainant, the Domain Name has been configured with Mail Exchange records to enable sending and receiving emails from the Domain Name, which, together with forms collecting user information on the Website, creates a risk of phishing (see W.W. Grainger, Inc. v. WhoisGuard Protected, WhoisGuard, Inc. / Daniel Thomas, WIPO Case No. D2020-1740). Finally, the Respondent’s failure to reply to the cease-and-desist letters or the present proceeding further supports a finding of bad faith. For the reasons discussed above, the Panel finds the third element of the Policy has been established. 7. Decision For the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the Domain Name <novozymes.info> be transferred to the Complainant. /Piotr Nowaczyk/ Piotr Nowaczyk Sole Panelist Date: May 13, 2026

Source of record: WIPO . Reproduced for research; WIPO is the authoritative source.